- $15.82m
- -$10.53m
- 15
- 46
- 40
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.29% | ||
| Return on Equity | -54.54% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.56 | 2.01 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Directors
- Sam Lee PRE (61)
- James Martin CCE (54)
- Roger Kornberg DRC (74)
- Richard Pfenniger DRC (65)
- Phillip Frost IND (84)
- Anthony Japour IND (61)
- Steven Rubin IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 21st, 2014
- Public Since
- March 12th, 2018
- No. of Shareholders
- 434
- No. of Employees
- 12
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 10,173,790
- Address
- 19805 N Creek Pkwy, BOTHELL, 98011-8251
- Web
- https://www.cocrystalpharma.com/
- Phone
- +1 7864591831
- Contact
- Jody Cain
- Auditors
- Weinberg & Company
Upcoming Events for COCP
Cocrystal Pharma Inc Annual Shareholders Meeting
Q2 2024 Cocrystal Pharma Inc Earnings Release
Similar to COCP
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Cocrystal Pharma share price?
As of Today at 13:05 UTC, shares in Cocrystal Pharma are trading at $1.56. This share price information is delayed by 15 minutes.
How has the Cocrystal Pharma share price performed this year?
Shares in Cocrystal Pharma last closed at $1.56 and the price had moved by -37.8% over the past 365 days. In terms of relative price strength the Cocrystal Pharma share price has underperformed the S&P500 Index by -49.15% over the past year.
What are the analyst and broker recommendations for Cocrystal Pharma?
The overall consensus recommendation for Cocrystal Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cocrystal Pharma dividend yield?
Cocrystal Pharma does not currently pay a dividend.
Does Cocrystal Pharma pay a dividend?
Cocrystal Pharma does not currently pay a dividend.
When does Cocrystal Pharma next pay dividends?
Cocrystal Pharma does not currently pay a dividend.
How do I buy Cocrystal Pharma shares?
To buy shares in Cocrystal Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cocrystal Pharma?
As of the previous close price of $1.56, shares in Cocrystal Pharma had a market capitalisation of $15.82m.
Where are Cocrystal Pharma shares listed?
Here are the trading details for Cocrystal Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: COCP
What kind of share is Cocrystal Pharma?
Based on an overall assessment of its quality, value and momentum Cocrystal Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cocrystal Pharma share price forecast for 2024?
The analyst consensus target price for shares in Cocrystal Pharma is $8.67. That is 457.56% above the last closing price of $1.56.
Analysts covering Cocrystal Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.30 for the next financial year.
What is the trend in the Cocrystal Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cocrystal Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -22.06%.
As of the last closing price of $1.56, shares in Cocrystal Pharma were trading -17.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cocrystal Pharma PE Ratio?
The Cocrystal Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cocrystal Pharma?
Cocrystal Pharma's management team is headed by:
- Sam Lee - PRE
- James Martin - CCE
- Roger Kornberg - DRC
- Richard Pfenniger - DRC
- Phillip Frost - IND
- Anthony Japour - IND
- Steven Rubin - IND